 |
市场调查报告书
商品编码
1634627
GLP-1 类似物市场：现况分析与未来预测（2024-2032）GLP-1 Analogues Market: Current Analysis and Forecast (2024-2032) |
||||||
GLP-1 类似物市场预计将大幅成长，预测期内（2024-2032 年）的复合年增长率为 28%。此外，对减肥解决方案的需求不断增加以及心血管益处的不断扩大也在推动市场的发展。新的药物传递方法的出现，特别是口服製剂和长效类似物的开发，也增加了这些药物的采用。此外，患者对糖尿病认识程度的提高和政府的推广也改善了市场准入。
2023 年6 月12 日，默克公司（NYSE：MRK，在美国和加拿大以外称为MSD）将在欧洲肝病研究协会(EASL) 年度会议上提交一份基于临床试验的临床试验报告会议于 6 月 21 日至 24 日举行，宣布有关 GLP-1/胰高血糖素受体共激动剂 efinopentide (MK-6024) 的新发现已被接受进行口头报告。
根据适应症，市场细分为度拉糖肽（Trulicity）、艾塞那肽（Baydureon、Byetta）、利拉鲁肽（Victoza、Saxenda）、索马鲁肽（Ozempic、Wegovy、Ryvelsus）和替泽帕肽（Maunjaro、Zepbound）。 2023年，利拉鲁肽（Victoza、Saxenda）将占较大的市占率。利拉鲁肽是该领域的主要促进因素，因为它是一种多用途 GLP-1，可有效治疗第 2 型糖尿病和肥胖症，并具有心血管作用。该产品以 Victoza 和 Saxenda 两个商品名销售，分别用于治疗糖尿病和治疗肥胖症，其多功能性意味着它拥有更广泛的市场基础。此外，每家公司都专注于扩大适应症、加强行销策略以及透过交付系统确保合规性。例如，2024 年6 月24 日，Teva Pharmaceutical Industries Ltd. 的美国子公司Teva Pharmaceuticals, Inc.（纽约证券交易所和特拉维夫证券交易所股票代码：TEVA）宣布已获得VictozaR1（利拉鲁肽注射液1.8 毫克）在美国。
根据应用，市场分为第 2 型糖尿病和减肥。 2023年，第2型糖尿病将占市场的很大占有率。全球 2 型糖尿病的盛行率不断上升，需要利拉鲁肽等 GLP-1 类似物来帮助控制血糖水平，同时促进减肥。由于此类药物具有多方面的价值，它们逐渐比传统药物更受青睐。此外，公司正在透过扩展到成长领域并与医疗机构合作来鼓励早期发现，从而改善获取资讯的机会。
根据分销管道，市场分为医院、零售药局和网路药局。预计预测期内（2024-2032 年），零售药局将以显着的复合年增长率成长。零售药局在 GLP-1 类似物的分销中发挥关键作用，注重可及性和用户需求。其覆盖范围有助于製造商进入两个市场，尤其是城市和农村地区，从而提高了需求。他们预计将与零售连锁店建立持续的关係，并提供培训和支持计划，以提高意识并改善对治疗计划的依从性。
为了更瞭解 GLP-1 类似物的市场采用情况，市场分为北美（美国、加拿大和北美其他地区）、欧洲（德国、法国、英国、西班牙、义大利和欧洲其他地区）、亚太地区（分析基于主要地区（中国、日本、印度、亚太其他地区）和其他地区的全球影响力。预计预测期内（2024-2032 年）亚太地区将实现显着的复合年增长率。背后的原因是糖尿病盛行率不断上升、城市化发展以及医疗成本不断上升。此外，人们对正确糖尿病管理意识的不断增强，推动了中国、印度和日本等主要地区领先的糖尿病管理解决方案的成长。此外，企业也十分重视透过合併、收购、合资、自有生产设施、在地化广告技术等方式扩大覆盖范围。更重要的是，监管部门的批准和低成本产品的供应对于新市场至关重要。此外，所涉及的电子健康技术和远距医疗正在帮助农村地区的医疗机构接触和接待入院患者。
市场的主要参与者包括 Novo Nordisk A/S、Lilly、Sanofi、AstraZeneca、Pfizer Inc.、Boehringer Ingelheim International GmbH、Amgen Inc.、ZEALAND PHARMA、Merck &Co.。
目录
第一章 市场概览
- 市场定义
- 主要目的
- 利害关係人
- 限制
第 2 章 研究方法或假设
- 研究过程
- 研究方法
- 受访者资料
第 3 章执行摘要
- 产业摘要
- 各细分市场的展望
- 市场成长强劲
- 区域展望
第 4 章 市场动态
- 驱动程式
- 机会
- 阻碍因素
- 趋势
- PESTEL 分析
- 需求方分析
- 供给面分析
- 合併和收购
- 投资场景
- 产业洞察：领先的新创公司及其独特策略
第 5 章 定价分析
- 按地区进行价格分析
- 影响价格的因素
6. 2022 年至 2032 年全球 GLP-1 类似物市场收入
第 7 章。
- 度拉鲁肽（Trulicity）
- 艾塞那肽（Bydureon、Byetta）
- 利拉鲁肽（Victoza、Saxenda）
- 索马鲁肽（Ozempic、Wegovy、Rybelsus）
- Tirzepatid（Maunjaro，Zepbound）
第 8 章市场洞察：按应用
- 2 型糖尿病
- 减肥
第 9 章。
- 医院
- 零售药局
- 网路药局
第 10 章 市场洞察：按地区
- 北美洲
- 美国
- 加拿大
- 其他北美地区
- 欧洲
- 德国
- 法国
- 英国
- 西班牙
- 义大利
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 其他亚太地区
- 世界其他地区
第 11 章 价值链分析
- 边际分析
- 市场参与者名单
第 12 章 竞争格局
- 竞争资讯中心
- 竞争市场定位分析
- 波特五力分析
第 13 章 公司简介
- Novo Nordisk A/S
- Company Overview
- Key Financials
- SWOT Analysis
- Product Portfolio
- Recent Developments
- Lilly
- Sanofi
- AstraZeneca
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Amgen Inc.
- ZEALAND PHARMA
- Merck & Co., Inc.
- Hanmi Pharm.Co.,Ltd.
第 14 章 缩写与先决条件
第 15 章附录
- 医院
- 零售药局
- 网路药局
第 10 章 市场洞察：按地区
- 北美洲
- 美国
- 加拿大
- 其他北美地区
- 欧洲
- 德国
- 法国
- 英国
- 西班牙
- 义大利
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 其他亚太地区
- 世界其他地区
第 11 章 价值链分析
- 边际分析
- 市场参与者名单
第 12 章 竞争格局
- 竞争资讯中心
- 竞争市场定位分析
- 波特五力分析
第 13 章 公司简介
- Novo Nordisk A/S
- Company Overview
- Key Financials
- SWOT Analysis
- Product Portfolio
- Recent Developments
- Lilly
- Sanofi
- AstraZeneca
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Amgen Inc.
- ZEALAND PHARMA
- Merck & Co., Inc.
- Hanmi Pharm.Co.,Ltd.
第 14 章 缩写与先决条件
第 15 章附录
GLP-1 (Glucagon-Like Peptide-1) receptors agonists are copies of the naturally occurring GLP-1 hormone that have been modified in some way to make it more effective in treatment. They have an important role in the treatment of type 2 diabetes and obesity as they stimulate the release of insulin, suppress glucagon, decelerate gastric emptying, and increase satiety. These drugs assist in glycemic control and allow for effective weight loss, the two effects being protective of the heart in diabetic patients.
The GLP-1 Analogues Market is expected to grow with a significant CAGR of 28% during the forecast period (2024-2032) due to type 2 diabetes and obesity have risen significantly over the recent past all over the world. Further, increasing the demand for weight loss solutions as well as expanding cardiovascular effectivity scope drive the market. The availability of new methods of drug delivery, especially including oral preparations and the development of long-acting analogues also increases the adoption of the drug. Furthermore, increased patient awareness levels and government promotion related to diabetes improve market access.
On June 12, 2023, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new findings for efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21-24.
Based on the indication, the market is segmented into Dulaglutide (Trulicity), Exenatide (Bydureon, Byetta), Liraglutide (Victoza, Saxenda), Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound). The Liraglutide (Victoza, Saxenda) held a significant share of the market in 2023. Liraglutide is an area's key driver of growth because it is a miscellaneous GLP-1 that is effective in the treatment of both type 2 diabetes and obesity with cardiovascular effects. The versatility of the product, which goes under the brand name Victoza for diabetes and Saxenda for obesity, means a wider market base. Moreover, companies concentrate on approaches to enlarging indications, enhancing marketing initiatives, and ensuring greater compliance through delivery systems. For instance, on June 24, 2024, Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced the launch of an authorized generic of Victoza(R)1 (liraglutide injection 1.8mg), in the United States.
Based on application, the market is segmented into type 2 diabetes and weight loss. Type 2 diabetes held a significant share of the market in 2023. The increasing global incidence of type 2 diabetes leads to the need for more GLP-1 analogues such as liraglutide that help to manage blood sugar levels while promoting weight loss. Such drugs are progressively preferred with respect to conventional treatments for their multiple valued aspects. Moreover, companies are improving access by expanding into growth lots and partnering with healthcare facilities exerting pressure for early detection.
Based on the distribution channel, the market is segmented into hospitals, retail pharmacies, and online pharmacies. The retail pharmacies are expected to grow with a significant CAGR during the forecast period (2024-2032). Retail pharmacies have an important function in the probabilities of the distribution of GLP-1 analogues, focusing on accessibility and demand by users. Their coverage assists manufacturers in accessing the two markets, especially the urban and the rural areas, making the demand higher. It is required to establish ongoing relations with retail chains, raise awareness and provide training and support programs that would increase compliance with therapy regimens.
For a better understanding of the market adoption of GLP-1 Analogues, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is because of a growing incidence of diabetes, the growth of cities, and, lastly, the increase in health care costs. Adding to this, the increased concerns among people regarding proper diabetes management drive the growth of superior diabetes management solutions in key areas such as China, India, and Japan. Moreover, companies pay much attention to growing the coverage through mergers, acquisitions, joint ventures, and own production facilities as well as localized advertisement techniques. More importantly, the approval of regulators and the availability of low-cost products are essential for new markets. Further, the concerned e-health technologies and telemedicine are helping the healthcare unit inpatient reach and compliance in rural areas.
Some of the major players operating in the market include Novo Nordisk A/S, Lilly, Sanofi, AstraZeneca, Pfizer Inc., Boehringer Ingelheim International GmbH, Amgen Inc., ZEALAND PHARMA, Merck & Co., Inc., Hanmi Pharm.Co.,Ltd.
TABLE OF CONTENTS
1.MARKET INTRODUCTION
- 1.1. Market Definitions
- 1.2. Main Objective
- 1.3. Stakeholders
- 1.4. Limitation
2.RESEARCH METHODOLOGY OR ASSUMPTION
- 2.1. Research Process of the GLP-1 Analogues Market
- 2.2. Research Methodology of the GLP-1 Analogues Market
- 2.3. Respondent Profile
3.EXECUTIVE SUMMARY
- 3.1. Industry Synopsis
- 3.2. Segmental Outlook
- 3.2.1. Market Growth Intensity
- 3.3. Regional Outlook
4.MARKET DYNAMICS
- 4.1. Drivers
- 4.2. Opportunity
- 4.3. Restraints
- 4.4. Trends
- 4.5. PESTEL Analysis
- 4.6. Demand Side Analysis
- 4.7. Supply Side Analysis
- 4.7.1. Merger & Acquisition
- 4.7.2. Investment Scenario
- 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies
5.PRICING ANALYSIS
- 5.1. Regional Pricing Analysis
- 5.2. Price Influencing Factors
6.GLOBAL GLP-1 ANALOGUES MARKET REVENUE (USD BN), 2022-2032F
7.MARKET INSIGHTS BY INDICATION
- 7.1. Dulaglutide (Trulicity)
- 7.2. Exenatide (Bydureon, Byetta)
- 7.3. Liraglutide (Victoza, Saxenda)
- 7.4. Semaglutide (Ozempic, Wegovy, Rybelsus)
- 7.5. Tirzepatide (Mounjaro, Zepbound)
8.MARKET INSIGHTS BY APPLICATION
- 8.1. Type 2 Diabetes
- 8.2. Weight Loss
9.MARKET INSIGHTS BY DISTRIBUTION CHANNEL
- 9.1. Hospitals
- 9.2. Retail Pharmacies
- 9.3. Online Pharmacies
10.MARKET INSIGHTS BY REGION
- 10.1. North America
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
- 10.2. Europe
- 10.2.1. Germany
- 10.2.2. France
- 10.2.3. UK
- 10.2.4. Spain
- 10.2.5. Italy
- 10.2.6. Rest of Europe
- 10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of APAC
- 10.4. Rest of the World
11.VALUE CHAIN ANALYSIS
- 11.1. Marginal Analysis
- 11.2. List of Market Participants
12.COMPETITIVE LANDSCAPE
- 12.1. Competition Dashboard
- 12.2. Competitor Market Positioning Analysis
- 12.3. Porter Five Forces Analysis
13.COMPANY PROFILES
- 13.1. Novo Nordisk A/S
- 13.1.1. Company Overview
- 13.1.2. Key Financials
- 13.1.3. SWOT Analysis
- 13.1.4. Product Portfolio
- 13.1.5. Recent Developments
- 13.2. Lilly
- 13.3. Sanofi
- 13.4. AstraZeneca
- 13.5. Pfizer Inc.
- 13.6. Boehringer Ingelheim International GmbH
- 13.7. Amgen Inc.
- 13.8. ZEALAND PHARMA
- 13.9. Merck & Co., Inc.
- 13.10. Hanmi Pharm.Co.,Ltd.
